What Lengo Therapeutics does

Lengo Therapeutics is a privately-held, early-stage biopharmaceutical company founded in 2020 and headquartered in San Diego, California. The company is focused on the discovery and development of cancer treatments, operating with a small team of 11-50 employees. Its senior leadership includes CEO Enoch Kariuki, co-founder and Board member Tracy Saxton, Chief Development Officer Paul Pearson, Chief Medical Officer Diana Hausman, SVP Finance and Principal Accounting Officer Ingrid Simms, and SVP Brion W. Murray.

To date, the company has raised at least $15 million in an early-stage financing round led by Frazier Healthcare Partners in May 2020. Public information about specific drug candidates, target indications, modalities, or pipeline programs is not disclosed in the available source materials. The company's small headcount and single disclosed funding round are consistent with a pre-clinical or early-clinical stage of operations typical of newly formed oncology-focused biotechs.

The leadership team's background — including executives with prior roles at kinase-focused oncology companies — suggests a strategic orientation toward precision oncology drug discovery. However, the source materials do not explicitly disclose Lengo's therapeutic targets, compound classes, clinical milestones, or external partnerships, and no commercial revenue, customer base, or product approvals are documented.

Name

Lengo Therapeutics

Legal name

Blueprint Medicines Corporation

Website

https://lengotx.com

Company type

Public

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Lengo Therapeutics is a privately-held, early-stage biopharmaceutical company founded in 2020 in San Diego, California, focused on the discovery and development of cancer treatments.

Ownership category

akta.pro rank

Product category

Oncology Pharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Cancer therapeutics
• Oncology drug discovery
• Biopharmaceutical development
• Precision oncology
• Novel cancer treatments

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from sales of approved medicines including AYVAKIT (avapritinib) for treatment of systemic mastocytosis and gastrointestinal stromal tumors. Product sales through pharmacy distribution and hospital channels with marketing authorization in US and Europe.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

Lengo Therapeutics is a biopharmaceutical company focused on the discovery and development of cancer treatments. The company is engaged in early-stage oncology drug discovery, identifying and advancing novel therapeutic candidates targeting cancer indications. As a pre-commercial biopharmaceutical firm, Lengo Therapeutics is building its pipeline of oncology assets through proprietary drug discovery and development activities.

Product overview

Blueprint Medicines is a biopharmaceutical company developing targeted therapies for allergic/inflammatory diseases and cancer. The company's product portfolio consists of approved medicines and investigational programs: AYVAKIT® (avapritinib) is an approved kinase inhibitor with indications for systemic mastocytosis and gastrointestinal stromal tumor; Elenestinib is an advancing development program for mastocytosis; and BLU-808 represents planned development for urticaria and other mast cell-mediated diseases. The company operates a discovery and development platform focused on kinome science to target the root causes of disease.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• Four-year sustained benefit and long-term safety data demonstrated in PIONEER trial for AYVAKIT in indolent systemic mastocytosis

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• SanoficoreOthersSanofi acquired Blueprint Medicines, making it a Sanofi company. The acquisition provides Blueprint Medicines with the resources and global infrastructure of a major pharmaceutical company while maintaining its scientific focus on targeted kinase therapies.

Recent moves4 records

Expansion highlights2 records

Broad incumbents

• Blueprint Medicines: Blueprint Medicines is a kinase-focused biopharmaceutical company now part of Sanofi, developing targeted therapies for systemic mastocytosis, GIST, and other cancers. It serves as a mature, larger-scale comparable in the same targeted oncology/kinase space Lengo is pursuing.
• Mirati Therapeutics: Mirati Therapeutics was a precision oncology biotech acquired by Bristol-Myers Squibb, focused on targeted therapies for genetically defined cancers. It serves as a successful comparable exit pathway for an oncology biotech of Lengo's profile.

Direct peers

• Black Diamond Therapeutics: Black Diamond Therapeutics is a clinical-stage precision oncology biotech developing small-molecule kinase inhibitors against genetically defined cancers. It is directly comparable to Lengo as a small, discovery-to-clinical-stage targeted oncology company.
• Erasca: Erasca is a San Diego-based precision oncology company focused on small-molecule kinase inhibitors for RAS/MAPK pathway cancers. It is a directly comparable peer given geographic overlap and similar targeted oncology mechanism approach.
• Nuvalent: Nuvalent is a clinical-stage biotech developing precisely designed kinase inhibitors for oncology. It represents a directly comparable peer for Lengo in the targeted kinase inhibitor space with a similar small-team, capital-efficient operating model.
• Foghorn Therapeutics: Foghorn Therapeutics is a clinical-stage oncology biotech focused on chromatin biology and targeted cancer therapies. It is comparable to Lengo as a similarly sized, discovery-to-clinical-stage oncology platform company pursuing novel cancer mechanisms.
• Cogent Biosciences: Cogent Biosciences is a precision oncology company developing kinase inhibitors for genomically defined cancers and rare diseases. It is a directly comparable peer to Lengo in the targeted oncology kinase space.

Emerging players

• Theseus Pharmaceuticals: Theseus Pharmaceuticals was an early-stage oncology biotech developing kinase inhibitors targeting resistance mutations, directly analogous to Lengo's targeted cancer treatment focus, though at a slightly more advanced clinical stage.
• Schrödinger: Schrödinger operates a computational drug discovery platform with a focus on oncology and other therapeutic areas. It represents an emerging adjacent peer given Lengo's potential need for computational and structure-based discovery capabilities.
• RayzeBio: RayzeBio was an emerging radiopharmaceutical oncology company acquired by Bristol-Myers Squibb. It is a thematically comparable peer demonstrating the M&A exit pathway for small, focused oncology biotechs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xtwitter.com/BlueprintMeds
• LinkedInlinkedin.com/company/blueprint-medicines

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lengo Therapeutics